A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19

DOI record: { "DOI": "10.1007/s40121-024-00992-5", "ISSN": [ "2193-8229", "2193-6382" ], "URL": "http://dx.doi.org/10.1007/s40121-024-00992-5", "alternative-id": [ "992" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "20 March 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "8 May 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "21 May 2024" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of Interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "Albert Qin and Chan-Yen Tsai work for PharmaEssentia Corporation. Wang-Huei Sheng serves as a consultant of PharmaEssentia Corporation. The other authors do not have conflict of interest to declare." }, { "group": { "label": "Ethical Approval", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "The study was conducted in accordance with the Helsinki Declaration of 2008. The study protocol and informed consent form (ICF) were approved by the Institutional Review Boards of National Taiwan University Hospital, Taipei Medical University, and all other participating hospitals. The committee names and the approval numbers are provided in supplemental Table . ICF including the consents of study participation and publication was obtained from all patients prior to their participation. This study was registered at ClinicalTrials.gov (NCT05770466)." } ], "author": [ { "affiliation": [], "family": "Liu", "given": "Wang-Da", "sequence": "first" }, { "affiliation": [], "family": "Feng", "given": "Po-Hao", "sequence": "additional" }, { "affiliation": [], "family": "Cheng", "given": "Chien-Yu", "sequence": "additional" }, { "affiliation": [], "family": "Chou", "given": "Chun-Liang", "sequence": "additional" }, { "affiliation": [], "family": "Lee", "given": "Chih-Hsin", "sequence": "additional" }, { "affiliation": [], "family": "Lu", "given": "Min-Chi", "sequence": "additional" }, { "affiliation": [], "family": "Liu", "given": "Po-Yu", "sequence": "additional" }, { "affiliation": [], "family": "Lee", "given": "Mei-Hui", "sequence": "additional" }, { "affiliation": [], "family": "Liao", "given": "Chun-Hsing", "sequence": "additional" }, { "affiliation": [], "family": "Chen", "given": "Mei-Chuan", "sequence": "additional" }, { "affiliation": [], "family": "Chen", "given": "Cheng-Pin", "sequence": "additional" }, { "affiliation": [], "family": "Hsu", "given": "Shang-Fu", "sequence": "additional" }, { "affiliation": [], "family": "Tzeng", "given": "Yu-Tien", "sequence": "additional" }, { "affiliation": [], "family": "Lin", "given": "Yi-Chun", "sequence": "additional" }, { "affiliation": [], "family": "Ou", "given": "Tsong-Yih", "sequence": "additional" }, { "affiliation": [], "family": "Qin", "given": "Albert", "sequence": "additional" }, { "affiliation": [], "family": "Tsai", "given": "Chan-Yen", "sequence": "additional" }, { "affiliation": [], "family": "Shih", "given": "Weichung Joe", "sequence": "additional" }, { "affiliation": [], "family": "Lee", "given": "Kang-Yun", "sequence": "additional" }, { "affiliation": [], "family": "Sheng", "given": "Wang-Huei", "sequence": "additional" } ], "container-title": "Infectious Diseases and Therapy", "container-title-short": "Infect Dis Ther", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2024, 5, 21 ] ], "date-time": "2024-05-21T12:02:11Z", "timestamp": 1716292931000 }, "deposited": { "date-parts": [ [ 2024, 7, 2 ] ], "date-time": "2024-07-02T05:28:20Z", "timestamp": 1719898100000 }, "funder": [ { "name": "PharmaEssentia Corporation" } ], "indexed": { "date-parts": [ [ 2024, 7, 3 ] ], "date-time": "2024-07-03T00:13:25Z", "timestamp": 1719965605795 }, "is-referenced-by-count": 0, "issue": "7", "issued": { "date-parts": [ [ 2024, 5, 21 ] ] }, "journal-issue": { "issue": "7", "published-print": { "date-parts": [ [ 2024, 7 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 5, 21 ] ], "date-time": "2024-05-21T00:00:00Z", "timestamp": 1716249600000 } }, { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 5, 21 ] ], "date-time": "2024-05-21T00:00:00Z", "timestamp": 1716249600000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s40121-024-00992-5.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s40121-024-00992-5/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s40121-024-00992-5.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "page": "1575-1588", "prefix": "10.1007", "published": { "date-parts": [ [ 2024, 5, 21 ] ] }, "published-online": { "date-parts": [ [ 2024, 5, 21 ] ] }, "published-print": { "date-parts": [ [ 2024, 7 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1126/sciadv.ade8778", "doi-asserted-by": "crossref", "key": "992_CR1", "unstructured": "Moghadasi SA, Heilmann E, Khalil AM, Nnabuife C, Kearns FL, Ye C, et al. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Sci Adv 2023;9:eade8778." }, { "DOI": "10.1007/s11845-021-02820-y", "author": "A Vitiello", "doi-asserted-by": "publisher", "first-page": "2367", "journal-title": "Ir J Med Sci", "key": "992_CR2", "unstructured": "Vitiello A. Sars-Cov-2 and risk of antiviral drug resistance. Ir J Med Sci. 2022;191:2367–8.", "volume": "191", "year": "2022" }, { "DOI": "10.1007/s43440-022-00388-7", "author": "L Rahmah", "doi-asserted-by": "publisher", "first-page": "1255", "journal-title": "Pharmacol Rep", "key": "992_CR3", "unstructured": "Rahmah L, Abarikwu SO, Arero AG, Essouma M, Jibril AT, Fal A, et al. Oral antiviral treatments for COVID-19: opportunities and challenges. Pharmacol Rep. 2022;74:1255–78.", "volume": "74", "year": "2022" }, { "DOI": "10.1016/j.celrep.2021.109415", "doi-asserted-by": "crossref", "key": "992_CR4", "unstructured": "Hoffmann M, Hofmann-Winkler H, Krüger N, Kempf A, Nehlmeier I, Graichen L, et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep 2021;36:109415." }, { "DOI": "10.1016/j.it.2021.02.003", "author": "C King", "doi-asserted-by": "publisher", "first-page": "312", "journal-title": "Trends Immunol", "key": "992_CR5", "unstructured": "King C, Sprent J. Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation. Trends Immunol. 2021;42:312–22.", "volume": "42", "year": "2021" }, { "DOI": "10.1016/j.ijid.2021.08.044", "author": "BLS Bhushan", "doi-asserted-by": "publisher", "first-page": "281", "journal-title": "Int J Infect Dis", "key": "992_CR6", "unstructured": "Bhushan BLS, Wanve S, Koradia P, Bhomia V, Soni P, Chakraborty S, et al. Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study. Int J Infect Dis. 2021;111:281–7.", "volume": "111", "year": "2021" }, { "DOI": "10.1007/s12325-021-01998-y", "author": "KY Chen", "doi-asserted-by": "publisher", "first-page": "910", "journal-title": "Adv Ther", "key": "992_CR7", "unstructured": "Chen KY, Lee KY, Qin A, Luo CS, Yeh YK, Zheng JQ, et al. Clinical experience with ropeginterferon alfa-2b in the off-label use for the treatment of COVID-19 patients in Taiwan. Adv Ther. 2022;39:910–22.", "volume": "39", "year": "2022" }, { "key": "992_CR8", "unstructured": "National Institutes of Health. COVID-19 treatment guidelines. Last Updated: March 6, 2023. Available on: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/" }, { "DOI": "10.1056/NEJMoa2209760", "author": "G Reis", "doi-asserted-by": "publisher", "first-page": "518", "journal-title": "N Engl J Med", "key": "992_CR9", "unstructured": "Reis G, Moreira Silva EAS, Medeiros Silva DC, Thabane L, Campos VHS, Ferreira TS, et al. Early treatment with pegylated interferon lambda for COVID-19. N Engl J Med. 2023;388:518–28.", "volume": "388", "year": "2023" }, { "DOI": "10.1128/JVI.01410-20", "author": "KG Lokugamage", "doi-asserted-by": "publisher", "first-page": "e01410", "journal-title": "J Virol", "key": "992_CR10", "unstructured": "Lokugamage KG, Hage A, deVries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, et al. Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. J Virol. 2020;94:e01410-e1420.", "volume": "94", "year": "2020" }, { "DOI": "10.1016/j.antiviral.2020.104811", "author": "E Mantlo", "doi-asserted-by": "publisher", "journal-title": "Antiviral Res", "key": "992_CR11", "unstructured": "Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020;179: 104811.", "volume": "179", "year": "2020" }, { "DOI": "10.1007/s40261-021-01026-5", "author": "N Miyachi", "doi-asserted-by": "publisher", "first-page": "391", "journal-title": "Clin Drug Investig", "key": "992_CR12", "unstructured": "Miyachi N, Zagrijtschuk O, Kang L, Yonezu K, Qin A. Pharmacokinetics and pharmacodynamics of ropeginterferon alfa-2b in healthy Japanese and Caucasian subjects after single subcutaneous administration. Clin Drug Investig. 2021;41:391–404.", "volume": "41", "year": "2021" }, { "DOI": "10.1111/bcp.15176", "author": "YW Huang", "doi-asserted-by": "publisher", "first-page": "2396", "journal-title": "Br J Clin Pharmacol", "key": "992_CR13", "unstructured": "Huang YW, Qin A, Fang J, Wang TF, Tsai CW, Lin KC, et al. Novel long-acting ropeginterferon alfa-2b: pharmacokinetics, pharmacodynamics, and safety in a phase I clinical trial. Br J Clin Pharmacol. 2022;88:2396–407.", "volume": "88", "year": "2022" }, { "DOI": "10.1007/s12325-021-01863-y", "author": "YW Huang", "doi-asserted-by": "publisher", "first-page": "4756", "journal-title": "Adv Ther", "key": "992_CR14", "unstructured": "Huang YW, Tsai CY, Tsai CW, Wang W, Zhang JJ, Qin A, et al. Pharmacokinetics and pharmacodynamics of novel long-acting ropeginterferon alpha-2b in healthy Chinese subjects. Adv Ther. 2021;38:4756–70.", "volume": "38", "year": "2021" }, { "DOI": "10.3390/v14061128", "author": "YW Huang", "doi-asserted-by": "publisher", "first-page": "1128", "journal-title": "Viruses", "key": "992_CR15", "unstructured": "Huang YW, Qin A, Tsai CY, Chen PJ. Novel pegylated interferon for the treatment of chronic viral hepatitis. Viruses. 2022;14:1128.", "volume": "14", "year": "2022" }, { "DOI": "10.1002/jgh3.12825", "author": "CY Chen", "doi-asserted-by": "publisher", "first-page": "782", "journal-title": "JGH Open.", "key": "992_CR16", "unstructured": "Chen CY, Chuang WL, Qin A, Zhang WH, Zhu LY, Zhang GQ, et al. A phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C. JGH Open. 2022;6:782–91.", "volume": "6", "year": "2022" }, { "DOI": "10.3389/fonc.2023.1109866", "author": "A Qin", "doi-asserted-by": "publisher", "first-page": "1109866", "journal-title": "Front Oncol", "key": "992_CR17", "unstructured": "Qin A, Urbansky RW, Yu L, Ahmed T, Mascrenhas J. An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: an overview of previous and ongoing studies with perspectives on the future. Front Oncol. 2023;13:1109866.", "volume": "13", "year": "2023" }, { "DOI": "10.2217/fon-2022-1141", "doi-asserted-by": "crossref", "key": "992_CR18", "unstructured": "Jin J, Qin A, Zhang L, Shen WH, Wang W, Zhang JJ, et al. A phase 2 trial to assess the efficacy and safety of ropeginterferon alfa-2b in Chinese patients with polycythemia vera. Future Oncol 2023;Online ahead of print." }, { "DOI": "10.2217/fon-2022-0596", "author": "S Verstovsek", "doi-asserted-by": "publisher", "first-page": "2999", "journal-title": "Future Oncol", "key": "992_CR19", "unstructured": "Verstovsek S, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, et al. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022;18:2999–3009.", "volume": "18", "year": "2022" }, { "DOI": "10.1002/jgh3.12613", "author": "HH Lin", "doi-asserted-by": "publisher", "first-page": "929", "journal-title": "JGH Open.", "key": "992_CR20", "unstructured": "Lin HH, Hsu SJ, Lu SN, Chuang WL, Hsu CW, Chien RN, et al. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: pharmacokinetics, safety, and preliminary efficacy. JGH Open. 2021;5:929–40.", "volume": "5", "year": "2021" }, { "DOI": "10.1016/j.jfma.2020.09.018", "author": "SJ Hsu", "doi-asserted-by": "publisher", "first-page": "956", "journal-title": "J Formos Med Assoc", "key": "992_CR21", "unstructured": "Hsu SJ, Yu ML, Su CW, Peng CY, Chien RN, Lin HH, et al. Ropeginterferon alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. J Formos Med Assoc. 2021;120:956–64.", "volume": "120", "year": "2021" }, { "DOI": "10.1007/s12072-020-10098-y", "author": "YW Huang", "doi-asserted-by": "publisher", "first-page": "997", "journal-title": "Hepatol Int", "key": "992_CR22", "unstructured": "Huang YW, Hsu CW, Lu SN, Yu ML, Su CW, Su WW, et al. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. Hepatol Int. 2020;14:997–1008.", "volume": "14", "year": "2020" }, { "key": "992_CR23", "unstructured": "WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020 Aug;20(8):e192-e197." }, { "DOI": "10.1016/j.rxeng.2020.11.001", "doi-asserted-by": "crossref", "key": "992_CR24", "unstructured": "Martínez Chamorro E, Díez Tascón A, Ibáñez Sanz L, Ossaba Vélez S, Borruel Nacenta S. Radiologic diagnosis of patients with COVID-19. Radiologia (Engl Ed). 2021 Jan-Feb;63(1):56–73." }, { "DOI": "10.4269/ajtmh.21-0606", "author": "S Abd-Elsalam", "doi-asserted-by": "publisher", "first-page": "886", "journal-title": "Am J Trop Med Hyg", "key": "992_CR25", "unstructured": "Abd-Elsalam S, Salama M, Soliman S, Naguib AM, Ibrahim IS, Torky M, et al. Remdesivir efficacy in COVID-19 treatment: a randomized controlled trial. Am J Trop Med Hyg. 2021;106:886–90. https://doi.org/10.4269/ajtmh.21-0606.", "volume": "106", "year": "2021" }, { "key": "992_CR26", "unstructured": "Shih W, Aisner J. Statistical design and analysis of clinical trials: principles and methods. 1st ed. Chapman & Hall/CRC Biostatistics Series; 2015." }, { "DOI": "10.1201/9781315183084", "doi-asserted-by": "crossref", "key": "992_CR27", "unstructured": "Chow SC, Shao J, Wang HS, Lokhnygina Y. Sample Size calculations in clinical research 3rd ed. Chapman & Hall/CRC Biostatistics Series; 2017." }, { "author": "WD Liu", "first-page": "00039", "issue": "24", "journal-title": "J Microbiol Immunol Infect", "key": "992_CR28", "unstructured": "Liu WD, Wang JT, Shih MC, Chen KH, Huang ST, Huang CF, et al. Effect of early dexamethasone on outcomes of COVID-19: A quasi-experimental study using propensity score matching. J Microbiol Immunol Infect. 2024;S1684–1182(24):00039–42.", "volume": "S1684–1182", "year": "2024" }, { "DOI": "10.1038/s41422-022-00619-9", "author": "D Bojkova", "doi-asserted-by": "publisher", "first-page": "319", "journal-title": "Cell Res", "key": "992_CR29", "unstructured": "Bojkova D, Widera M, Ciesek S, Wass MN, Michaelis M, Cinatl J Jr. Reduced interferon antagonism but similar drug sensitivity in omicron variant compared to delta variant of SARS-CoV-2 isolates. Cell Res. 2022;32:319–21.", "volume": "32", "year": "2022" }, { "DOI": "10.1038/s41421-022-00408-z", "author": "D Bojkova", "doi-asserted-by": "publisher", "first-page": "42", "journal-title": "Cell Discov.", "key": "992_CR30", "unstructured": "Bojkova D, Rothenburger T, Ciesek S, Wass MN, Michaelis M, Cinatl J Jr. SARS-CoV-2 omicron variant virus isolates are highly sensitive to interferon treatment. Cell Discov. 2022;8:42.", "volume": "8", "year": "2022" }, { "DOI": "10.1016/j.drup.2023.100986", "author": "A Vitiello", "doi-asserted-by": "publisher", "journal-title": "Drug Resist Updat", "key": "992_CR31", "unstructured": "Vitiello A, Zovi A, Rezza G. New emerging SARS-CoV-2 variants and antiviral agents. Drug Resist Updat. 2023;70: 100986.", "volume": "70", "year": "2023" }, { "DOI": "10.1016/j.immuni.2019.03.025", "author": "HM Lazear", "doi-asserted-by": "publisher", "first-page": "907", "journal-title": "Immunity", "key": "992_CR32", "unstructured": "Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity. 2019;50:907–23.", "volume": "50", "year": "2019" }, { "DOI": "10.1016/j.chom.2020.05.008", "author": "A Park", "doi-asserted-by": "publisher", "first-page": "870", "journal-title": "Cell Host Microbe", "key": "992_CR33", "unstructured": "Park A, Iwasaki A. Type I and type III interferons- induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27:870–8.", "volume": "27", "year": "2020" }, { "DOI": "10.3389/fimmu.2021.648004", "doi-asserted-by": "crossref", "key": "992_CR34", "unstructured": "Contoli M, Papi A, Tomassetti L, Rizzo P, Vieceli Dalla Sega F, Fortini F, et al. Blood interferon-α levels and severity, outcomes, and inflammatory profiles in hospitalized COVID-19 patients. Front Immunol 2021;12:648004." }, { "DOI": "10.1126/science.abc6027", "author": "J Hadjadj", "doi-asserted-by": "publisher", "first-page": "718", "journal-title": "Science", "key": "992_CR35", "unstructured": "Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–24.", "volume": "369", "year": "2020" }, { "DOI": "10.1016/S2213-2600(20)30566-X", "author": "JJ Feld", "doi-asserted-by": "publisher", "first-page": "498", "journal-title": "Lancet Respir Med", "key": "992_CR36", "unstructured": "Feld JJ, Kandel C, Biondi MJ, Kozak RA, Zahoor MA, Lemieux C, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med. 2021;9:498–510.", "volume": "9", "year": "2021" } ], "reference-count": 36, "references-count": 36, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s40121-024-00992-5" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "13" }